Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
CHATZIKONSTANTINOU, Thomas; Lydia SCARFO; Eva MINGA; Georgios KARAKATSOULIS; Dimitra CHAMOU et al.
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Autoři
CHATZIKONSTANTINOU, Thomas; Lydia SCARFO; Eva MINGA; Georgios KARAKATSOULIS; Dimitra CHAMOU; Jana KOTAŠKOVÁ; Gloria IACOBONI; Christos DEMOSTHENOUS; Elisa ALBI; Miguel ALCOCEBA; Salem AL-SHEMARI; Therese AURRAN-SCHLEINITZ; Francesca BACCHIARRI; Sofia CHATZILEONTIADOU; Rosa COLLADO; Zadie DAVIS; de Deus Santos Marcos DANIEL; Maria DIMOU; Elena DMITRIEVA; David DONALDSON; Dos Santos GIMENA; Barbara DRETA; Maria EFSTATHOPOULOU; Shaimaa EL-ASHWAH; Alicia ENRICO; Andrzej FRYGIER; Sara GALIMBERTI; Andrea GALITZIA; Eva GIMENO; Valerio GUARENTE; Romain GUIEZE; Sean HARROP; Eleftheria HATZIMICHAEL; Yair HERISHANU; Jose-angel HERNANDEZ-RIVAS; Ozren JAKSIC; Elzbieta KALICINSKA; Kamel LARIBI; Volkan KARAKUS; Arnon P KATER; Bonnie KHO; Maria KISLOVA; Eliana KONSTANTINOU; Maya KOREN-MICHOWITZ; Ioannis KOTSIANIDIS; Zuzana KUBOVA; Jorge LABRADOR; Deepesh LAD; Luca LAURENTI; Thomas LONGVAL; Alberto LOPEZ-GARCIA; Juan MARQUET; Stanislava MAŠLEJOVÁ; Carlota MAYOR-BASTIDA; Biljana MIHALJEVIC; Ivana MILOSEVIC; Fatima MIRAS; Riccardo MOIA; Marta MORAWSKA; Uttam K NATH; Almudena NAVARRO-BAILON; Jacopo OLIVIERI; Irina PANOVSKA-STAVRIDIS; Maria PAPAIOANNOU; Cheyenne PIERIE; Anna PUIGGROS; Gianluigi REDA; Gian M RIGOLIN; Rosa RUCHLEMER; Mattia SCHIPANI; Annett SCHIWITZA; Yandong SHEN; Tereza SHOKRALLA; Martin SIMKOVIC; Svetlana SMIRNOVA; Dina S A SOLIMAN; Stephan STILGENBAUER; Tamar TADMOR; Kristina TOMIC; Eric TSE; Theodoros VASSILAKOPOULOS; Andrea VISENTIN; Candida VITALE; George VRACHIOLIAS; Vojin VUKOVIC; Renata WALEWSKA; Zhenshu XU; Munci YAGCI; Lucrecia YANEZ; Mohamed YASSIN; Jana ZUCHNICKA; David OSCIER; Alessandro GOZZETTI; Panagiotis PANAGIOTIDIS; Francesc BOSCH; Paolo SPORTOLETTI; Blanca ESPINET; Gerassimos A PANGALIS; Viola M POPOV; Stephen MULLIGAN; Maria ANGELOPOULOU; Fatih DEMIRKAN; Tomas PAPAJIK; Bella BIDERMAN; Roberta MURRU; Marta COSCIA; Constantine TAM; Antonio CUNEO; Gianluca GAIDANO; Rainer CLAUS; Niki STAVROYIANNI; Livio TRENTIN; Darko ANTIC; Lukas SMOLEJ; Olga B KALASHNIKOVA; Mark CATHERWOOD; Martin SPACEK; Šárka POSPÍŠILOVÁ; Michael DOUBEK; Eugene NIKITIN; Anastasia CHATZIDIMITRIOU; Paolo GHIA a Kostas STAMATOPOULOS
Novel small molecule inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Indeed, BTK (BTKi) and BCL2 inhibitors (BCL2i) alone or in combination with each other or other compounds have proven superior to chemoimmunotherapy (CIT) in both the frontline and the relapsed/refractory (R/R) setting.1 ERIC, the European Research Initiative on CLL, conducted this international multicenter retrospective study focused on the era of CIT, aiming to (i) reveal the treatment patterns in the “real world” and (ii) assess the outcomes of patients who received frontline treatment between 2000 and 2016. Overall, 7382 patients with CLL (7134, 96.6%) or SLL (248, 3.4%) from 76 centers in 25 countries in five continents were included. The median age at diagnosis was 64 (interquartile range [IQR]: 56–71) years and the median age at first treatment was 66 (IQR: 58–74) years. The median follow-up was 7.33 (IQR: 4.56–10.81) years from diagnosis and 5.27 (IQR: 3.04–7.99) from first treatment. The vast majority of patients (6873/7134, 93.2%) received at least one line of chemotherapy or CIT; only 197/7134 (2.7%) received exclusively novel agents. Baseline characteristics and disease-specific biomarkers are listed in Supporting Information Material. The most common first-line regimen was FCR (2609, 35.3%), mostly in young patients (median age at first treatment: 60 years, IQR: 54–66), followed by chlorambucil monotherapy (1293, 17.5%), mostly in older patients (median age at first treatment: 74 years, IQR: 65–80). BTKis as first-line treatment were used in 149/7134 (2%) patients who either participated in clinical trials and/or had TP53 aberrations; 20/7134 (0.3%) received frontline venetoclax-based regimens, all in the context of clinical trials (Figure 1). Detailed outcomes for the most common frontline regimens are provided in Supporting Information Material.
Návaznosti
LX22NPO5102, projekt VaV
Název: Národní ústav pro výzkum rakoviny (Akronym: NÚVR)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro výzkum rakoviny, 5.1 EXCELES
CHATZIKONSTANTINOU, Thomas; Lydia SCARFO; Eva MINGA; Georgios KARAKATSOULIS; Dimitra CHAMOU; Jana KOTAŠKOVÁ; Gloria IACOBONI; Christos DEMOSTHENOUS; Elisa ALBI; Miguel ALCOCEBA; Salem AL-SHEMARI; Therese AURRAN-SCHLEINITZ; Francesca BACCHIARRI; Sofia CHATZILEONTIADOU; Rosa COLLADO; Zadie DAVIS; de Deus Santos Marcos DANIEL; Maria DIMOU; Elena DMITRIEVA; David DONALDSON; Dos Santos GIMENA; Barbara DRETA; Maria EFSTATHOPOULOU; Shaimaa EL-ASHWAH; Alicia ENRICO; Andrzej FRYGIER; Sara GALIMBERTI; Andrea GALITZIA; Eva GIMENO; Valerio GUARENTE; Romain GUIEZE; Sean HARROP; Eleftheria HATZIMICHAEL; Yair HERISHANU; Jose-angel HERNANDEZ-RIVAS; Ozren JAKSIC; Elzbieta KALICINSKA; Kamel LARIBI; Volkan KARAKUS; Arnon P KATER; Bonnie KHO; Maria KISLOVA; Eliana KONSTANTINOU; Maya KOREN-MICHOWITZ; Ioannis KOTSIANIDIS; Zuzana KUBOVA; Jorge LABRADOR; Deepesh LAD; Luca LAURENTI; Thomas LONGVAL; Alberto LOPEZ-GARCIA; Juan MARQUET; Stanislava MAŠLEJOVÁ; Carlota MAYOR-BASTIDA; Biljana MIHALJEVIC; Ivana MILOSEVIC; Fatima MIRAS; Riccardo MOIA; Marta MORAWSKA; Uttam K NATH; Almudena NAVARRO-BAILON; Jacopo OLIVIERI; Irina PANOVSKA-STAVRIDIS; Maria PAPAIOANNOU; Cheyenne PIERIE; Anna PUIGGROS; Gianluigi REDA; Gian M RIGOLIN; Rosa RUCHLEMER; Mattia SCHIPANI; Annett SCHIWITZA; Yandong SHEN; Tereza SHOKRALLA; Martin SIMKOVIC; Svetlana SMIRNOVA; Dina S A SOLIMAN; Stephan STILGENBAUER; Tamar TADMOR; Kristina TOMIC; Eric TSE; Theodoros VASSILAKOPOULOS; Andrea VISENTIN; Candida VITALE; George VRACHIOLIAS; Vojin VUKOVIC; Renata WALEWSKA; Zhenshu XU; Munci YAGCI; Lucrecia YANEZ; Mohamed YASSIN; Jana ZUCHNICKA; David OSCIER; Alessandro GOZZETTI; Panagiotis PANAGIOTIDIS; Francesc BOSCH; Paolo SPORTOLETTI; Blanca ESPINET; Gerassimos A PANGALIS; Viola M POPOV; Stephen MULLIGAN; Maria ANGELOPOULOU; Fatih DEMIRKAN; Tomas PAPAJIK; Bella BIDERMAN; Roberta MURRU; Marta COSCIA; Constantine TAM; Antonio CUNEO; Gianluca GAIDANO; Rainer CLAUS; Niki STAVROYIANNI; Livio TRENTIN; Darko ANTIC; Lukas SMOLEJ; Olga B KALASHNIKOVA; Mark CATHERWOOD; Martin SPACEK; Šárka POSPÍŠILOVÁ; Michael DOUBEK; Eugene NIKITIN; Anastasia CHATZIDIMITRIOU; Paolo GHIA a Kostas STAMATOPOULOS. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. HemaSphere. Hoboken: Wiley, 2024, roč. 8, č. 9, s. 1-7. ISSN 2572-9241. Dostupné z: https://doi.org/10.1002/hem3.70004.
@article{2439137, author = {Chatzikonstantinou, Thomas and Scarfo, Lydia and Minga, Eva and Karakatsoulis, Georgios and Chamou, Dimitra and Kotašková, Jana and Iacoboni, Gloria and Demosthenous, Christos and Albi, Elisa and Alcoceba, Miguel and AlandShemari, Salem and AurranandSchleinitz, Therese and Bacchiarri, Francesca and Chatzileontiadou, Sofia and Collado, Rosa and Davis, Zadie and Daniel, de Deus Santos Marcos and Dimou, Maria and Dmitrieva, Elena and Donaldson, David and Gimena, Dos Santos and Dreta, Barbara and Efstathopoulou, Maria and ElandAshwah, Shaimaa and Enrico, Alicia and Frygier, Andrzej and Galimberti, Sara and Galitzia, Andrea and Gimeno, Eva and Guarente, Valerio and Guieze, Romain and Harrop, Sean and Hatzimichael, Eleftheria and Herishanu, Yair and HernandezandRivas, Joseandangel and Jaksic, Ozren and Kalicinska, Elzbieta and Laribi, Kamel and Karakus, Volkan and Kater, Arnon P and Kho, Bonnie and Kislova, Maria and Konstantinou, Eliana and KorenandMichowitz, Maya and Kotsianidis, Ioannis and Kubova, Zuzana and Labrador, Jorge and Lad, Deepesh and Laurenti, Luca and Longval, Thomas and LopezandGarcia, Alberto and Marquet, Juan and Mašlejová, Stanislava and MayorandBastida, Carlota and Mihaljevic, Biljana and Milosevic, Ivana and Miras, Fatima and Moia, Riccardo and Morawska, Marta and Nath, Uttam K and NavarroandBailon, Almudena and Olivieri, Jacopo and PanovskaandStavridis, Irina and Papaioannou, Maria and Pierie, Cheyenne and Puiggros, Anna and Reda, Gianluigi and Rigolin, Gian M and Ruchlemer, Rosa and Schipani, Mattia and Schiwitza, Annett and Shen, Yandong and Shokralla, Tereza and Simkovic, Martin and Smirnova, Svetlana and Soliman, Dina S A and Stilgenbauer, Stephan and Tadmor, Tamar and Tomic, Kristina and Tse, Eric and Vassilakopoulos, Theodoros and Visentin, Andrea and Vitale, Candida and Vrachiolias, George and Vukovic, Vojin and Walewska, Renata and Xu, Zhenshu and Yagci, Munci and Yanez, Lucrecia and Yassin, Mohamed and Zuchnicka, Jana and Oscier, David and Gozzetti, Alessandro and Panagiotidis, Panagiotis and Bosch, Francesc and Sportoletti, Paolo and Espinet, Blanca and Pangalis, Gerassimos A and Popov, Viola M and Mulligan, Stephen and Angelopoulou, Maria and Demirkan, Fatih and Papajik, Tomas and Biderman, Bella and Murru, Roberta and Coscia, Marta and Tam, Constantine and Cuneo, Antonio and Gaidano, Gianluca and Claus, Rainer and Stavroyianni, Niki and Trentin, Livio and Antic, Darko and Smolej, Lukas and Kalashnikova, Olga B and Catherwood, Mark and Spacek, Martin and Pospíšilová, Šárka and Doubek, Michael and Nikitin, Eugene and Chatzidimitriou, Anastasia and Ghia, Paolo and Stamatopoulos, Kostas}, article_location = {Hoboken}, article_number = {9}, doi = {https://doi.org/10.1002/hem3.70004}, keywords = {chronic lymphocytic leukemia}, language = {eng}, issn = {2572-9241}, journal = {HemaSphere}, title = {Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL}, url = {https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004}, volume = {8}, year = {2024} }
TY - JOUR ID - 2439137 AU - Chatzikonstantinou, Thomas - Scarfo, Lydia - Minga, Eva - Karakatsoulis, Georgios - Chamou, Dimitra - Kotašková, Jana - Iacoboni, Gloria - Demosthenous, Christos - Albi, Elisa - Alcoceba, Miguel - Al-Shemari, Salem - Aurran-Schleinitz, Therese - Bacchiarri, Francesca - Chatzileontiadou, Sofia - Collado, Rosa - Davis, Zadie - Daniel, de Deus Santos Marcos - Dimou, Maria - Dmitrieva, Elena - Donaldson, David - Gimena, Dos Santos - Dreta, Barbara - Efstathopoulou, Maria - El-Ashwah, Shaimaa - Enrico, Alicia - Frygier, Andrzej - Galimberti, Sara - Galitzia, Andrea - Gimeno, Eva - Guarente, Valerio - Guieze, Romain - Harrop, Sean - Hatzimichael, Eleftheria - Herishanu, Yair - Hernandez-Rivas, Jose-angel - Jaksic, Ozren - Kalicinska, Elzbieta - Laribi, Kamel - Karakus, Volkan - Kater, Arnon P - Kho, Bonnie - Kislova, Maria - Konstantinou, Eliana - Koren-Michowitz, Maya - Kotsianidis, Ioannis - Kubova, Zuzana - Labrador, Jorge - Lad, Deepesh - Laurenti, Luca - Longval, Thomas - Lopez-Garcia, Alberto - Marquet, Juan - Mašlejová, Stanislava - Mayor-Bastida, Carlota - Mihaljevic, Biljana - Milosevic, Ivana - Miras, Fatima - Moia, Riccardo - Morawska, Marta - Nath, Uttam K - Navarro-Bailon, Almudena - Olivieri, Jacopo - Panovska-Stavridis, Irina - Papaioannou, Maria - Pierie, Cheyenne - Puiggros, Anna - Reda, Gianluigi - Rigolin, Gian M - Ruchlemer, Rosa - Schipani, Mattia - Schiwitza, Annett - Shen, Yandong - Shokralla, Tereza - Simkovic, Martin - Smirnova, Svetlana - Soliman, Dina S A - Stilgenbauer, Stephan - Tadmor, Tamar - Tomic, Kristina - Tse, Eric - Vassilakopoulos, Theodoros - Visentin, Andrea - Vitale, Candida - Vrachiolias, George - Vukovic, Vojin - Walewska, Renata - Xu, Zhenshu - Yagci, Munci - Yanez, Lucrecia - Yassin, Mohamed - Zuchnicka, Jana - Oscier, David - Gozzetti, Alessandro - Panagiotidis, Panagiotis - Bosch, Francesc - Sportoletti, Paolo - Espinet, Blanca - Pangalis, Gerassimos A - Popov, Viola M - Mulligan, Stephen - Angelopoulou, Maria - Demirkan, Fatih - Papajik, Tomas - Biderman, Bella - Murru, Roberta - Coscia, Marta - Tam, Constantine - Cuneo, Antonio - Gaidano, Gianluca - Claus, Rainer - Stavroyianni, Niki - Trentin, Livio - Antic, Darko - Smolej, Lukas - Kalashnikova, Olga B - Catherwood, Mark - Spacek, Martin - Pospíšilová, Šárka - Doubek, Michael - Nikitin, Eugene - Chatzidimitriou, Anastasia - Ghia, Paolo - Stamatopoulos, Kostas PY - 2024 TI - Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL JF - HemaSphere VL - 8 IS - 9 SP - 1-7 EP - 1-7 PB - Wiley SN - 25729241 KW - chronic lymphocytic leukemia UR - https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004 N2 - Novel small molecule inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Indeed, BTK (BTKi) and BCL2 inhibitors (BCL2i) alone or in combination with each other or other compounds have proven superior to chemoimmunotherapy (CIT) in both the frontline and the relapsed/refractory (R/R) setting.1 ERIC, the European Research Initiative on CLL, conducted this international multicenter retrospective study focused on the era of CIT, aiming to (i) reveal the treatment patterns in the “real world” and (ii) assess the outcomes of patients who received frontline treatment between 2000 and 2016. Overall, 7382 patients with CLL (7134, 96.6%) or SLL (248, 3.4%) from 76 centers in 25 countries in five continents were included. The median age at diagnosis was 64 (interquartile range [IQR]: 56–71) years and the median age at first treatment was 66 (IQR: 58–74) years. The median follow-up was 7.33 (IQR: 4.56–10.81) years from diagnosis and 5.27 (IQR: 3.04–7.99) from first treatment. The vast majority of patients (6873/7134, 93.2%) received at least one line of chemotherapy or CIT; only 197/7134 (2.7%) received exclusively novel agents. Baseline characteristics and disease-specific biomarkers are listed in Supporting Information Material. The most common first-line regimen was FCR (2609, 35.3%), mostly in young patients (median age at first treatment: 60 years, IQR: 54–66), followed by chlorambucil monotherapy (1293, 17.5%), mostly in older patients (median age at first treatment: 74 years, IQR: 65–80). BTKis as first-line treatment were used in 149/7134 (2%) patients who either participated in clinical trials and/or had TP53 aberrations; 20/7134 (0.3%) received frontline venetoclax-based regimens, all in the context of clinical trials (Figure 1). Detailed outcomes for the most common frontline regimens are provided in Supporting Information Material. ER -
CHATZIKONSTANTINOU, Thomas; Lydia SCARFO; Eva MINGA; Georgios KARAKATSOULIS; Dimitra CHAMOU; Jana KOTAŠKOVÁ; Gloria IACOBONI; Christos DEMOSTHENOUS; Elisa ALBI; Miguel ALCOCEBA; Salem AL-SHEMARI; Therese AURRAN-SCHLEINITZ; Francesca BACCHIARRI; Sofia CHATZILEONTIADOU; Rosa COLLADO; Zadie DAVIS; de Deus Santos Marcos DANIEL; Maria DIMOU; Elena DMITRIEVA; David DONALDSON; Dos Santos GIMENA; Barbara DRETA; Maria EFSTATHOPOULOU; Shaimaa EL-ASHWAH; Alicia ENRICO; Andrzej FRYGIER; Sara GALIMBERTI; Andrea GALITZIA; Eva GIMENO; Valerio GUARENTE; Romain GUIEZE; Sean HARROP; Eleftheria HATZIMICHAEL; Yair HERISHANU; Jose-angel HERNANDEZ-RIVAS; Ozren JAKSIC; Elzbieta KALICINSKA; Kamel LARIBI; Volkan KARAKUS; Arnon P KATER; Bonnie KHO; Maria KISLOVA; Eliana KONSTANTINOU; Maya KOREN-MICHOWITZ; Ioannis KOTSIANIDIS; Zuzana KUBOVA; Jorge LABRADOR; Deepesh LAD; Luca LAURENTI; Thomas LONGVAL; Alberto LOPEZ-GARCIA; Juan MARQUET; Stanislava MAŠLEJOVÁ; Carlota MAYOR-BASTIDA; Biljana MIHALJEVIC; Ivana MILOSEVIC; Fatima MIRAS; Riccardo MOIA; Marta MORAWSKA; Uttam K NATH; Almudena NAVARRO-BAILON; Jacopo OLIVIERI; Irina PANOVSKA-STAVRIDIS; Maria PAPAIOANNOU; Cheyenne PIERIE; Anna PUIGGROS; Gianluigi REDA; Gian M RIGOLIN; Rosa RUCHLEMER; Mattia SCHIPANI; Annett SCHIWITZA; Yandong SHEN; Tereza SHOKRALLA; Martin SIMKOVIC; Svetlana SMIRNOVA; Dina S A SOLIMAN; Stephan STILGENBAUER; Tamar TADMOR; Kristina TOMIC; Eric TSE; Theodoros VASSILAKOPOULOS; Andrea VISENTIN; Candida VITALE; George VRACHIOLIAS; Vojin VUKOVIC; Renata WALEWSKA; Zhenshu XU; Munci YAGCI; Lucrecia YANEZ; Mohamed YASSIN; Jana ZUCHNICKA; David OSCIER; Alessandro GOZZETTI; Panagiotis PANAGIOTIDIS; Francesc BOSCH; Paolo SPORTOLETTI; Blanca ESPINET; Gerassimos A PANGALIS; Viola M POPOV; Stephen MULLIGAN; Maria ANGELOPOULOU; Fatih DEMIRKAN; Tomas PAPAJIK; Bella BIDERMAN; Roberta MURRU; Marta COSCIA; Constantine TAM; Antonio CUNEO; Gianluca GAIDANO; Rainer CLAUS; Niki STAVROYIANNI; Livio TRENTIN; Darko ANTIC; Lukas SMOLEJ; Olga B KALASHNIKOVA; Mark CATHERWOOD; Martin SPACEK; Šárka POSPÍŠILOVÁ; Michael DOUBEK; Eugene NIKITIN; Anastasia CHATZIDIMITRIOU; Paolo GHIA a Kostas STAMATOPOULOS. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. \textit{HemaSphere}. Hoboken: Wiley, 2024, roč.~8, č.~9, s.~1-7. ISSN~2572-9241. Dostupné z: https://doi.org/10.1002/hem3.70004.
